The Vascular Genome as a Therapeutic Target: A Systematic Review of CRISPR-based Gene Editing In Vascular Disease
Cardiovascular Toxicology · 2026-08 · 26 (8)
DOI: 10.1007/s12012-026-10170-3 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Toxicology, online erschienen am 08.08.2026. Verfasst von Abiya Ahad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ananta Institute of Medical Sciences and Research Center, Rajsamand, Rajasthan, 313202, India. ahadabiya15@gmail.com. Hauptthemen laut MEDLINE: Gene Editing, Genetic Therapy, Vascular Diseases, CRISPR-Cas Systems. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Despite advances in therapy, arterial, venous, and pulmonary vascular diseases remain leading causes of morbidity and mortality. Persistent endothelial dysfunction, inflammation, oxidative stress, and maladaptive vascular remodeling continue to drive disease progression and residual risk. CRISPR/Cas9 technology offers a unique opportunity to modify the molecular pathways underlying vascular pathophysiology directly. The PRISMA 2020 guidelines guided the systematic review. The databases PubMed/MEDLINE, Embase, Web of Science, Cochrane Library, ClinicalTrials.gov, and Google Scholar were searched from their inception until September 2025 for experimental and/or clinical studies evaluating the application of CRISPR/Cas9 on vascular disease. Included were in vitro studies, animal model studies, and early-phase human studies aimed at targeting the endothelial cell regulatory pathways, inflammatory pathways, metabolic remodeling processes, and hereditary causes of vasculopathy. Seventeen studies met the inclusion criteria. CRISPR technologies targeting PCSK9, NOS3, HIF1A, NLRP3, METTL4, BMPR2, and ACTA2 were identified to enhance repair mechanisms in endothelial cells, regulate inflammation, modulate lipid metabolism, and remodel the vascular system. The human studies demonstrated sustained gene silencing effects following a single dose of CRISPR-induced in vivo editing. The use of CRISPR technology to edit cell genomes offers potential to alter disease progression in vascular medicine, with a growing body of translational evidence supporting the feasibility and durability of the approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ananta Institute of Medical Sciences and Research Center, Rajsamand, Rajasthan, 313202, India. ahadabiya15@gmail.com.
- MercyOne Clinton Medical Center, Clinton, IA, USA.
- Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
- Medical Park Ankara Hospital, Ankara, Turkey.
- Osh State Medical University, Osh, Kyrgyzstan.
- GMERS Medical College, Vadodara, Gujarat, India.
ORCID-Profile: Abiya Ahad
Zitieren
APA
Ahad, A., Hullon, D., Singh, T., Dabiry, S. M., Sakthivel, L., Padaria, J., Rekhraj, A. S., & Bhattacharjee, A. (2026). The Vascular Genome as a Therapeutic Target: A Systematic Review of CRISPR-based Gene Editing In Vascular Disease. Cardiovascular Toxicology, 26(8). https://doi.org/10.1007/s12012-026-10170-3
Vancouver
Ahad A, Hullon D, Singh T, Dabiry SM, Sakthivel L, Padaria J, et al. The Vascular Genome as a Therapeutic Target: A Systematic Review of CRISPR-based Gene Editing In Vascular Disease. Cardiovascular Toxicology. 2026;26(8). doi:10.1007/s12012-026-10170-3
BibTeX
@article{Ahad2026,
author = {Ahad, Abiya and Hullon, Darshan and Singh, Tanya and Dabiry, Sultan Mujib and Sakthivel, Lalenthika and Padaria, Jeel and Rekhraj, Akshay Singh and Bhattacharjee, Aditya},
title = {The Vascular Genome as a Therapeutic Target: A Systematic Review of CRISPR-based Gene Editing In Vascular Disease},
journal = {Cardiovascular Toxicology},
year = {2026},
volume = {26},
number = {8},
doi = {10.1007/s12012-026-10170-3}
}
EUVIMED